Vol 5, No 6 (2016)
Other materials agreed with the Editors
Published online: 2017-03-31
Clinical value of glargine 300 U/mL based on randomized trials and routine medical practice
DOI: 10.5603/DK.2016.0035
Clin Diabetol 2016;5(6):203-207.
Abstract
The paper presents available evidence on the clinical use of glargine 300 IU/mL, the latest addition to the diabetes care armamentarium.
Keywords: glarginetype 2 diabetesinsulin therapy
References
- Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32(6): 478–496.
- Sutton G, Minguet J, Ferrero C, et al. U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014; 14(12): 1849–1860.
- Summary of Product Characteristics Toujeo. www.ema.europa.eu (07.02.2017).
- Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015; 17(3): 254–260.
- Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000; 50(3): 161–167.
- Becker RHA, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015; 38(4): 637–643.
- Becker RHA, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015; 17(3): 261–267.
- Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: Clinical implications. Indian J Endocrinol Metab. 2013; 17(4): 611–619.
- Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014; 15(10): 18381–18406.
- Torimoto K, Okada Y, Mori H, et al. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013; 12: 1.
- Riddle MC, Bolli GB, Ziemen M, et al. EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014; 37(10): 2755–2762.
- Yki-Järvinen H, Bergenstal R, Ziemen M, et al. EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014; 37(12): 3235–3243.
- Bolli GB, Riddle MC, Bergenstal RM, et al. on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015; 17(4): 386–394.
- Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015; 38(12): 2217–2225.
- Ritzel R, Roussel R, Giaccari A et al. glycemic control and hypoglycemia with insulin glargine 300 U/mL (Gla300) vs. glargine 100 U/mL (Gla100) in type 2 diabetes (T2DM) in a patient level metaanalysis of 1Yr phase 3a EDITION studies. Poster presentation at ADA. http://app.core-apps.com/tristar-ada15/abstracts. (5-9.06.2015).
- Tong L, Wang H, Gupta S et al. Effect of switching to insulin glargine 300 U/mL on clinical outcomes in patients with type 2 diabetes: a medical chart-review study in the US. Poster presentation at 14th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC);. http://www.kantarhealth.com/clinical-publications (1-3.12.2016).
- Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Diabetologia Kliniczna. 2016; 5(Suppl A).
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364–1379.
- Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51(3): 408–416.
- Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008; 30(11): 1976–1987.
- Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010; 33(6): 1176–1178.
- Jakobsen M, Dalsgaard M, Hørmann M, et al. Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocr Disord. 2012; 12: 21.
- McAdam-Marx C, Yu J, Bouchard J, et al. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin. 2010; 26(1): 191–201.
- Feinkohl I, Aung PP, Keller M, et al. Edinburgh Type 2 Diabetes Study (ET2DS) Investigators. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014; 37(2): 507–515.
- Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab. 2013; 15(6): 546–557.
- Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013; 36: 138.
- Jeandidier N, Riddle MC, Bolli GB et al. New insulin glargine 300 U/mL: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus. Poster presentation at EASD 2014, . http://www.easdvirtualmeeting.org/resources/18792 (07.02.2017).
- Wang H, Zhang Q, Frois C et al. Safety and Efficacy of Insulin Glargine 300 U/mL (Gla-300) compared with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM) — A Network Meta-analysis (NMA). Oral presentation at ADA, 5–9 June 2015, Boston, MA, USA. http://app.core-apps.com/tristarada15/abstracts.